This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Awaad, Y. Articles by Coyne, M. F. Search for Related Content PubMed PubMed Citation Articles by Awaad, Y. Articles by Coyne, M. F. Social Bookmarking                         What's this?

Treatment of Childhood Myoclonus With Botulinum Toxin Type A

Children's Hospital of Michigan, Neurology Division, the Movement Disorder Clinic, Wayne State University, School of Medicine Detroit, MI, yawaad{at}med.wayne.edu

Hassan Tayem, MD

Children's Hospital of Michigan, Neurology Division, the Movement Disorder Clinic, Wayne State University, School of Medicine Detroit, MI

Ahmad Elgamal, MD

Children's Hospital of Michigan, Neurology Division, the Movement Disorder Clinic, Wayne State University, School of Medicine Detroit, MI

Martha F. Coyne, BA

Bio-logic Systems Corporation Mundelein, IL

Because of inadequate response to or intolerable side effects of oral medication, nine patients with segmental, generalized, and focal myoclonus were treated with intramuscular botulinum toxin type A. All patients were evaluated with neuroimaging, routine and limb-monitored electroencephalography, electromyography, evoked potentials and appropriate biochemical studies. Patients were aged 2 to 22 years, with duration of myoclonus from 1 month to 10 years. Multiple medication trials included antiepileptic drugs, benzodiazepines, tryptophan, L-dopa/carbidopa, baclofen, and dantrolene. Patients were injected with botulinum toxin in their affected area with electromyographic guidance to affected muscles with different doses (8 to 20 units/kg), except two patients who were injected with 32 and 45 units/kg, respectively, at 4- to 8-month intervals. One patient did not complete botulinum toxin treatment because of subjective weakness, although there were virtually no side effects reported in patients completing therapy. Patients reported a dramatic reduction in painful myoclonus. In addition, patients exhibited improved functional skills, as demonstrated by markedly improved use of affected extremities and improvements in ambulation. One patient, who was nonambulatory prior to treatment, was able to walk afterward. Long-term benefits could be related to higher dosage used or negative feedback effect. (J Child Neurol 1999;14:781-786).

Journal of Child Neurology, Vol. 14, No. 12, 781-786 (1999)
DOI: 10.1177/088307389901401203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?